Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04940533 · ClinicalTrials.gov registry record
Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers
A clinical trial, sponsored by University of Minnesota.
- Not yet
- Registry status
- 30
- Enrollment target
NCT04940533 is a clinical trial that has not yet begun recruiting, run by University of Minnesota. The registered enrollment target is 30 participants.
The verdict
NCT04940533 has not yet begun recruiting, sponsored by University of Minnesota.
- NOT YET RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study aims to evaluate the pharmacokinetic changes during pregnancy, postpartum, and in breast milk in cystic fibrosis patients receiving a cystic fibrosis transmembrane conductance regulator (CTFR) modulator, including Elexacaftor, Tezacaftor, Ivacaftor, or Lumacaftor.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2027-01-01 |
| Est. Completion | 2028-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04940533
The ClinicalTrials.gov registry entry for NCT04940533 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04940533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04940533 about?
NCT04940533 is a clinical study titled "Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers". This study aims to evaluate the pharmacokinetic changes during pregnancy, postpartum, and in breast milk in cystic fibrosis patients receiving a cystic fibrosis transmembrane conductance regulator (CTFR) modulator, including Elexacaftor, Tezacaftor, Ivacaftor, or Lumacaftor.
What is the current status of trial NCT04940533?
This trial is currently not yet recruiting. The enrollment target is 30 participants. The study started on 2027-01-01. Estimated completion is 2028-07-01.
Who is sponsoring clinical trial NCT04940533?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.